SPRC SciSparc Ltd

NEUTRAL Impact: 4/10 PRESS-RELEASE
Horizon weeks Filed Jun 4, 2026 Processed 2d 10h ago Wire GlobeNewswire
Press release: announcement
Latest settled — T+1d ⚠ clustered
SPRC ▼ -0.87% at T+1d
NEUTRAL call ✗ call lost -0.87% · α vs SPY +1.73% · entry $11.54 → $11.44
Next anchor: T+5d in 5d
Currently $11.44 · -0.87% from $11.54 entry
Entry anchored
Jun 3, 04:19 PM ET
via Databento tick
T+1d
-0.87%
call -0.87% · α +1.73%
$11.44
settled yesterday
T+5d
call — · α —
in 5d
T+20d
call — · α —
in 27d
T+60d
call — · α —
in 3mo

Price Chart

Loading chart...

Executive Summary

SciSparc's majority-owned subsidiary NeuroThera closed its acquisition of a ~54% interest in CliniQuantum for ~CAD$9.5M in stock, with potential earn-out payments up to US$2.5M. This is a small, non-cash deal for a micro-cap biotech with no immediate revenue impact, and the historical calibration shows prior neutral reports on SPRC have underperformed significantly at T+20.

Key Financial Metrics

Deal Value
$9.5M

Actionable Insight

The deal adds a speculative quantum analytics angle but no near-term revenue. Given SPRC's micro-cap status and poor historical T+20 performance, traders should treat this as a non-event for the parent stock. Monitor for any future CliniQuantum milestones that could trigger earn-outs.

Key Facts

  • NeuroThera acquired ~54% of CliniQuantum for ~CAD$9.5M in stock (56.6M shares).
  • Earn-out payments up to US$2.5M contingent on patent filings and fundraising milestones.
  • CliniQuantum holds a license for quantum simulation technology applied to clinical trial data.
  • SciSparc's market cap is ~$5M; the deal is small relative to the parent company's size.
  • Historical SPRC reports show a 0% win rate at T+20 with an average alpha of -26.39%.

Financial Impact

Consideration of ~CAD$9.5M in NeuroThera shares; earn-out up to US$2.5M over 3 years. No cash outlay.

dilutionshare count

Risk Factors

  • Dilution from NeuroThera share issuance to CliniQuantum sellers.
  • Earn-out milestones may never be achieved; no guaranteed return.
  • SPRC's low liquidity and small market cap amplify volatility on any news.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3306664
7 reports for SPRC
Performance horizon
Filters
Rows
Reports for SPRC — sortable, filterable
Type Now
Jun 4, 2026
2d ago
6-K
NEUTRAL ★ 4/10
$11.54 $11.44▼ −0.87%▲ +1.73%$11.44 (−0.87%)
Jun 4, 2026
2d ago
Press Release
NEUTRAL ★ 4/10
$11.54 $11.44▼ −0.87%▲ +1.73%$11.44 (−0.87%)
May 29, 2026
8d ago
6-K
NEUTRAL ★ 4/10
$9.81 $10.59▲ +7.95%▲ +7.68%$11.44 (+16.62%)
May 28, 2026
9d ago
Press Release
NEUTRAL ★ 4/10
$10.55 $9.81▼ −7.01%▼ −7.26%$11.44 (+8.44%)
Mar 16, 2026
11w ago
Press Release
NEUTRAL ★ 4/10
$4.32 $4.62▲ +6.94%▲ +6.67%$11.44 (+164.81%)
Mar 12, 2026
12w ago
Press Release
MIXED ★ 5/10
$4.73 $4.36▼ −7.82%▼ −7.22%$11.44 (+141.86%)
Mar 10, 2026
12w ago
Press Release
MIXED ★ 6/10
$4.02 $3.85▼ −4.23%▼ −4.12%$11.44 (+184.58%)
Showing 7 of 7

US Market Status

Market Closed — Opens Mon (14h 56m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access